STM JOURNALS

Journal of
Polymer & Composites

ISSN: 2321-2810 (Online)
ISSN: 2321-8525 (Print)
Volume 14, Special Issue 1, 2026
DOI (Journal): 10.37591/JoPC

https://journals.stmjournals.com/jopc

Review JoPC

Revolutionizing the Delivery and Efficacy of Nutraceuticals

Vema Kiran[1,*], J. Divija[2], Abhitosh Kumar Pandey[3], A. Sharanya[4], A. Jyothi[5]

Abstract

The global nutraceutical market is on a remarkable growth trajectory, fueled by a growing public focus on preventive health and expected to surpass USD 900 billion by 2030. However, a major roadblock stands in the way of many promising bioactive compounds—like resveratrol, curcumin, and omega-3s—reaching their full potential: their poor absorption by our bodies. Issues like low solubility in water, instability in the gut, and rapid metabolism lead to notoriously low oral bioavailability, meaning we often get only a fraction of the intended benefit. This review explores how advanced delivery systems, crafted from innovative polymers and composite materials, are providing solutions to these challenges. We take a close look at cutting-edge encapsulation technologies such as solid lipid nanoparticles (SLNs), liposomes, nanoemulsions, and phytosomes. The article breaks down the materials used (like chitosan, alginate, and PLGA), how they're made, and the clever mechanisms they use to enhance the stability, absorption, and targeted delivery of nutraceuticals. We also discuss how these systems are being woven into functional foods and personalized nutrition, while honestly addressing the hurdles of scaling up production, navigating regulatory landscapes, and the exciting future of smart, responsive systems and 3D printing. By merging material science with nutritional pharmacology, these advanced delivery platforms are transforming nutraceuticals from poorly absorbed supplements into potent, reliable, and essential tools for modern, evidence-based healthcare.

Keywords: Nutraceuticals, bioavailability, nanoencapsulation, polymeric nanoparticles, lipid nanocarriers, composite mater

INTRODUCTION

Over the last ten years, we've seen a dramatic shift in consumer awareness about how diet influences health and disease prevention. This has rocketed the nutraceutical industry—a blend of "nutrition" and "pharmaceutical"—into a massive global market. It was valued at USD 591.1 billion in 2024 and is expected to grow robustly to USD 919.1 billion by 2030 [1]. Nutraceuticals are bioactive compounds from food sources with proven health benefits, spanning everything from dietary supplements and fortified foods to medicinal foods [2]. Compounds like curcumin, resveratrol, omega-3s, and probiotics offer therapeutic potential through various actions, including fighting oxidation and inflammation, modulating the immune system, and regulating metabolism [3, 4].

Despite their promise and popularity, a critical problem prevents them from delivering their full effect: notoriously poor bioavailability. Many of the most powerful nutraceuticals are held back by their inherent physical and chemical properties, which severely limit how well our bodies can absorb and use them [5].

***Author for Correspondence**
Vema Kiran

[1]Professor, Department of Pharmaceutics, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India
[2]Student, Department of Pharmaceutics, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India
[3–5]Student, Department of Pharmaceutics, MB School of Pharmaceutical Sciences, Mohan Babu University, Tirupati, Andhra Pradesh, India

Received Date: August 26, 2025
Accepted Date: October 06, 2025
Published Date: January 15, 2026

Citation: Vema Kiran, J. Divija, Abhitosh Kumar Pandey, A. Sharanya, A. Jyothi. Revolutionizing the Delivery and Efficacy of Nutraceuticals. Journal of Polymer & Composites. 2026; 14(Special Issue 1): S638–S647p.

These limitations include:

- Poor Aqueous Solubility: Many plant-based compounds are fat-loving (lipophilic), meaning they don't dissolve well in the watery environment of our digestive system, which is essential for absorption [6].
- Chemical Instability: These bioactive ingredients are often fragile. They can break down during processing, storage, or their journey through the gut due to exposure to oxygen, light, heat, or extreme pH levels [7].
- Low Permeability: Some compounds struggle to cross the intestinal lining into the bloodstream.
- Extensive Pre-systemic Metabolism: They are rapidly broken down by enzymes in the gut or processed by the liver (the "first-pass effect") before they ever reach circulation, drastically reducing the amount of active compound available [8].

For example, the powerful anti-inflammatory agent curcumin has an oral bioavailability of less than 1% [9]. Similarly, resveratrol shows high activity in lab studies but is very poorly absorbed in humans [10]. This huge gap between what works in a lab and what works in the human body is the single biggest challenge in nutraceutical science.

This is where the fields of material science and pharmaceutical technology offer a powerful solution. Advanced delivery systems, especially those engineered from polymers and composite materials, provide a sophisticated way to protect, encapsulate, and enhance the delivery of these sensitive bioactives [11]. By designing tiny micro- and nano-scale carriers, we can overcome these barriers, significantly improve bioavailability, ensure targeted delivery, and unlock the true clinical potential of nutraceuticals [12]. This review offers a comprehensive look at these revolutionary delivery systems that are finally bridging the gap between the promise of nutrition and the reality of therapeutic benefit.

Nutraceuticals play a pivotal role in bridging the gap between nutrition and medicine, offering significant potential for human health and disease prevention. These bioactive compounds, derived from food sources, provide health benefits beyond basic nutrition [13] They can modulate physiological functions, boost antioxidant defences, and reduce inflammation, which are key factors in chronic diseases. Regular consumption of specific nutraceuticals is linked to a reduced risk of conditions like cardiovascular disease, diabetes, and cancer [14]. By correcting nutritional deficiencies and enhancing the body's resilience, they serve as a proactive, complementary strategy for maintaining wellness and mitigating disease pathogenesis [15].

THE BIOAVAILABILITY BARRIER: A FORMIDABLE CHALLENGE

For any orally consumed bioactive compound to work, it must successfully travel from the mouth into the bloodstream and then to its site of action. This journey, known as bioavailability, depends entirely on the compound's solubility, permeability, and stability [16]. For nutraceuticals, this path is an obstacle course.

Solubility Limitations

Under the Biopharmaceutics Classification System (BCS), most nutraceuticals fall into Class II (low solubility, high permeability) or Class IV (low solubility, low permeability) [17]. While being fat-soluble (lipophilic) often makes a compound biologically active, it becomes a major problem in the watery environment of the gut. Compounds like curcumin, many flavonoids, and fat-soluble vitamins (A, D, E, K) simply can't dissolve effectively, which is the first essential step for absorption [18].

Instability in the GI Environment

The trip through the gastrointestinal (GI) tract is harsh. The stomach's acidic environment can destroy compounds sensitive to acid. Further down, the intestine is packed with enzymes that can metabolize and break down complex molecules before they have a chance to be absorbed [19]. For instance, many polyphenols are broken down by digestive enzymes and transformed by our gut bacteria, which can change their structure and activity [20].

Pre-systemic Metabolism

Once absorbed, nutraceuticals travel to the liver via the portal vein. Here, they undergo "first-pass metabolism," where liver enzymes (like cytochrome P450) and conjugation reactions (e.g., glucuronidation) process them [21]. This often converts the active compound into water-soluble metabolites that are easily excreted, drastically reducing the concentration of the original, active molecule that reaches our bloodstream.

Traditional formulation strategies like simple powders or tablets have largely failed to solve these problems. This failure has driven the need for more advanced, material-driven delivery systems designed specifically to shield these compounds and boost their bioavailability.

REVOLUTIONIZING IN MODERN NUTRACEUTICALS

The nutraceuticals industry is undergoing a paradigm shift, moving beyond simple dietary supplements towards a sophisticated, evidence-based model that is revolutionizing personalized health. The most transformative development is the move from a "one-size-fits-all" approach to AI-driven personalization, where algorithms analyse individual genetic, microbiome, and biomarker data to create bespoke formulations, thereby maximizing efficacy and moving into the realm of preventative medicine [22]. Concurrently, significant advancements are being made in bioavailability through advanced delivery systems. Technologies like liposomal encapsulation and nanoemulsions ensure that active ingredients are protected and effectively delivered to their target sites within the body, solving a long-standing challenge of poor absorption [23].

Furthermore, the focus has expanded to include the gut microbiome as a central therapeutic target. The industry is progressing beyond basic probiotics to include prebiotics and, more recently, postbiotics—the beneficial metabolites produced by gut bacteria—which offer a more direct and stable means of influencing host health [24]. The very sourcing of ingredients is being disrupted by biotechnology and precision fermentation. This method allows for the sustainable production of high-purity, "animal-free" bioactive compounds, such as human-identical milk oligosaccharides, creating a novel and scalable supply chain free from agricultural constraints [25]. This biotech revolution is part of a broader pharma-nutraceutical convergence, where ingredients are subjected to rigorous clinical trials to manage specific conditions, blurring the lines between food and medicine and providing physicians with validated, non-pharmaceutical tools. Finally, empowered by omics technologies (genomics, metabolomics), companies can now provide irrefutable, molecular-level evidence of a product's mechanism and efficacy, elevate the entire industry's scientific credibility and solidify its role in the future of proactive health management.

POLYMERIC AND COMPOSITE DELIVERY SYSTEMS: ENGINEERING SOLUTIONS

Advanced delivery systems use the unique properties of natural/synthetic polymers, lipids, and surfactants to create micro- and nano-sized environments that protect nutraceuticals and control how they are released and absorbed.

Lipid-Based Nanocarriers

Lipid-based systems are especially effective for fat-soluble nutraceuticals, as they keep the compounds dissolved throughout the GI tract.

- *Nanoemulsions:* These are tiny, kinetically stable droplets of oil dispersed in water (or vice versa), stabilized by an emulsifier, with droplet sizes typically between 20-200 nm [26]. The incredibly small size creates a huge surface area for digestion and absorption. They are excellent for delivering fish oils, vitamin E, carotenoids, and coenzyme Q10 [27]. The emulsifiers used prevent the droplets from clumping together and can even enhance permeability.
- *Liposomes:* These are spherical vesicles made of phospholipid bilayers surrounding a watery core. This clever structure allows them to encapsulate both water-soluble compounds (in the core) and fat-soluble ones (in the lipid shell) at the same time [28]. Liposomes protect their cargo from degradation and can fuse with cell membranes to aid absorption. They are widely studied for delivering vitamins, antioxidants, and flavonoids [29].

- *Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs):* SLNs are submicron particles made of a solid lipid matrix stabilized by surfactants [30]. They offer improved stability and controlled release compared to traditional emulsions. NLCs are a smarter, second generation made by mixing solid lipids with liquid oils. This creates a less organized matrix that can hold more drug and reduces the risk of the active ingredient being pushed out during storage [31]. Both are ideal for the controlled delivery of challenging compounds like curcumin and resveratrol [32].

Polymer-Based Nanocarriers

Polymeric nanoparticles provide precise control over release timing and boast high encapsulation efficiency.

- *Polymeric Nanoparticles:* These are solid colloidal particles where the bioactive is trapped within or attached to a polymer matrix. Biodegradable and biocompatible polymers are preferred. Common natural ones include: Chitosan: Has a positive charge and mucoadhesive properties, which help it stick to the gut lining longer and enhance permeability [33]. Alginate: Anionic and forms gentle gels, making it ideal for protecting sensitive probiotics [34]. Zein: A corn protein excellent for carrying hydrophobic compounds [35]. Synthetic polymers like PLGA are also popular for their finely tunable degradation rates [36].
- *Polymeric Micelles:* These are formed when amphiphilic block copolymers self-assemble in water, creating a hydrophobic core (to hold fat-soluble compounds) and a hydrophilic shell (for stability) [37]. They can improve the solubility of compounds like curcumin by orders of magnitude [38].

Hybrid and Complex Systems

- *Phytosomes:* These are advanced complexes where individual phytochemical molecules are bound to phospholipids (like phosphatidylcholine) [39]. This creates a molecule that is compatible with lipids, allowing it to integrate seamlessly into cell membranes and be absorbed much more efficiently than standard extracts [40]. Silymarin and curcumin phytosomes are well-known commercial successes.
- *Electrospun Fibers:* Electrospinning uses an electrical charge to draw ultra-fine fibers from a polymer solution. This creates non-woven mats of nanofibers perfect for encapsulation [41]. Using food-grade polymers like gelatin, zein, and pullulan, this technique can encapsulate heat-sensitive ingredients (e.g., probiotics, antioxidants) into edible films for food packaging or directly into food products [42]. A summary of these advanced systems is provided in "Table 1".

Table 1. Overview of advanced delivery systems for nutraceuticals.

Delivery system	Key Material (Polymers/ lipids)	Mechanism of enhancement	Nutraceutical Compound
Nanoemulsion	Edible oils, Tweens, Spans	Increases solubility & Surface area; protects from hydrolysis	Vitamin Omega-3 Lycopene
Liposome	Phosphatidylcholine, Cholesterol	Protects both hydrophilic & lipophilic cargo; enhances cellular uptake	Vitamin C, Curcumin, EGCG
SLN/NLC	Glyceryl monostearate Cetyl palmitate, Oils	Solid matrix controls release; protects from chemical degradation	Resveratrol, Curcumin, β-carotene
Polymeric Nanoparticle	Chitosan, Alginate, PLGA, Zein	Mucoadhesion; controlled & targeted release; enzymatic protection	Antioxidants, Probiotics
Polymer Micelles	Pluronics, PEG-PLA coplymers	Dramatically increases aqueous solubility	Curcumin, Paclitaxel (as supplement)
Phytosome	Phosphatidylcholine	Improves lipid solubility and absorption via cell membrane integration	Silymarin, Curcumin, Green tea extract
Electrospun Fibers	Gelatin, Zein, PVA	Creates protective stable matrices for sensitive compounds; food integration	Probiotics, Volatile antioxidants

FUNCTIONAL FOODS AND CONSUMER ACCEPTANCE

The real-world success of these advanced systems often hinges on their ability to be seamlessly integrated into foods without ruining taste, texture, or mouthfeel. The concept of "functional foods"—everyday foods fortified with encapsulated bioactive compounds—is a key application area [43].

- *Beverages:* Nanoemulsions and liposomes can fortify clear drinks with oil-soluble vitamins and antioxidants without making them cloudy or altering their flavor [44].
- *Dairy Products:* Yogurt and cheese are perfect for delivering encapsulated probiotics (protected from stomach acid) and omega-3s (protected from oxidation and off-flavours) [45].
- *Bakery Products:* SLNs and polymer-coated ingredients can incorporate heat-sensitive nutrients into baked goods, shielding them during the high-temperature baking process [46].
- *Consumer-Friendly Formats:* Beyond traditional foods, these systems enable appealing formats like chewable gummies (using gelatin matrices), effervescent tablets, and quick-dissolve films, which greatly improve compliance, especially for children and the elderly [47].

CHALLENGES, REGULATORY ASPECTS, AND FUTURE PERSPECTIVES

Despite their significant promise, moving these advanced delivery systems from the lab to the market faces several hurdles.

Scaling Up and Cost-Effectiveness

While there are many ways to create these systems in a lab, many nanoencapsulation techniques are complex and expensive to scale up for mass production. Processes like high-pressure homogenization (used for SLNs, NLCs, and nanoemulsions) have much greater potential for industrial scaling than more intricate lab techniques like electrospinning [48].

Regulatory and safety considerations

Nutraceuticals are not regulated like pharmaceuticals in most countries, due to fundamental differences in how they are categorized and intended to be used:

(a). *Categorized as Foods, Not Drugs:* Unlike drugs, nutraceuticals are classified as food products or dietary supplements. They are regulated under food safety laws, which focus on consumer safety and truthful labeling. Crucially, they are not required to undergo rigorous pre-market clinical trials to prove they can treat or prevent diseases. Oversight relies more on the precautionary principle for ingredient approval and strong post-market surveillance to catch any safety issues after the product is already for sale.

(b). *Different Regulatory Frameworks:* The regulatory paths for pharmaceuticals and nutraceuticals are worlds apart. Pharmaceuticals face mandatory, stringent scrutiny from agencies like the FDA (USA), EMA (Europe), or CDSCO (India). They must pass extensive clinical trials to prove safety, efficacy, and quality before they can ever be sold.

In stark contrast, nutraceuticals have a much lighter regulatory burden. In the U.S., the FDA does not pre-approve them. Manufacturers must ensure their products are safe and that their labels are truthful, but they don't have to prove efficacy to the FDA before marketing. The system is largely reactive, with authorities stepping in only if problems like contamination or false advertising claims arise after the product is on shelves.

In India, the Food Safety and Standards Authority of India (FSSAI) regulates nutraceuticals as "Foods for Special Dietary Uses (FSDU)." While the FSSAI requires product registration and sets standards for ingredients and labeling, it does not demand the exhaustive pre-market clinical trials required for drugs. The focus is on safety and quality control, not on validating specific health claims with pharmaceutical-level rigor.

Intended Use and Claims

The fundamental distinction between pharmaceuticals and nutraceuticals lies in their intended use and the regulatory demands that follow. Pharmaceuticals are developed specifically to diagnose, cure,

mitigate, treat, or prevent disease. Consequently, they must undergo rigorous clinical testing to substantiate these therapeutic claims with robust scientific evidence of safety and efficacy prior to market approval. In contrast, nutraceuticals are intended to support overall health, supplement the diet, or maintain wellness. They are therefore restricted to making only general structure/function claims about nourishing the body; any explicit disease treatment claims are strictly prohibited unless the product is officially approved as a drug.

Scientific Evidence and Standardization

One of the critical distinctions between the nutraceutical and pharmaceutical industries lies in the standardized methods required to prove efficacy and ensure product quality. The pharmaceutical sector operates under a mandate of evidence-based medicine. This means that before a drug is approved for public use, it must successfully navigate a series of large-scale, randomized, double-blind clinical trials. These rigorous studies are designed to generate statistically significant data that conclusively demonstrates both safety and a specific therapeutic benefit for a defined medical condition.

In stark contrast, the nutraceutical landscape is characterized by a notable lack of such standardized, mandatory efficacy protocols. Many products are brought to market and their benefits are promoted primarily on the basis of traditional use, anecdotal evidence, or preliminary in vitro and animal studies. While these early findings can be valuable for generating hypotheses, they do not constitute the high-level clinical proof required for pharmaceuticals. This evidentiary gap is a direct consequence of their regulatory classification as dietary supplements or foods, which, unlike medicines, are not required to prove they work before being sold.

The result of this divergent regulatory approach is a market with highly variable product quality, potency, and batch-to-batch consistency. Without the stringent Good Manufacturing Practice (GMP) standards and purity and dosage specifications universally enforced for drugs, the actual active ingredient content in a nutraceutical can differ significantly from what is stated on the label. This variability can lead to ineffective products or, in cases of contamination or adulteration, potential consumer risk. Ultimately, while pharmaceuticals provide a predictable, standardized therapeutic effect, the consumer of nutraceuticals must navigate a market where the burden of proof for efficacy and quality is often shifted from the manufacturer to the consumer.

Regulatory Challenges

A fundamental challenge in regulating health products stems from the pervasive ambiguity and overlap in their definitions. Globally, there is no harmonized, legal distinction that clearly separates a nutraceutical from a pharmaceutical. This lack of a universal definition creates significant hurdles for international regulatory harmonization, as one country may classify a substance like high-dose melatonin as a prescription drug, while another treats it as an over-the-counter supplement.

This grey area is further complicated by a growing category of products that deliberately blur the traditional line between food and medicine. These include functional foods fortified with bioactive compounds, medical foods intended for specific dietary management of a disease, and probiotics making bold health claims. This ambiguity creates a regulatory quagmire where it becomes unclear which agency—food or drug—holds oversight authority. This jurisdictional confusion can lead to critical gaps in safety monitoring and creates opportunities for malpractices. Unscrupulous manufacturers may exploit these loopholes by engaging in mislabelling, concealing ingredient quantities, or making inappropriate or outright disease treatment claims that are forbidden for products not undergoing rigorous pharmaceutical approval. Consequently, this undefined landscape can mislead consumers and potentially compromise public health.

Market Considerations

The lighter regulatory framework governing nutraceuticals offers a distinct double-edged sword. On one hand, it significantly lowers the barriers to market entry, allowing for rapid product development

and marketing. This agility facilitates innovation, encourages a diverse and competitive marketplace, and provides consumers with a wide array of choices for supporting their health and wellness goals without needing a prescription. This model promotes preventative health autonomy and can swiftly respond to emerging nutritional trends.

However, this very lack of stringent pre-market oversight often comes at a cost, primarily in the consistent assurance of product safety, efficacy, and quality. Without mandatory rigorous clinical trials and stringent manufacturing audits, the market is susceptible to variability. This has led to recurring issues such as products that fail to contain their advertised ingredients in the correct potency, contamination with heavy metals or unapproved pharmaceutical agents, and advertising that makes misleading or scientifically unsubstantiated health claims.

In response to these documented quality lapses and safety incidents, calls for stricter, more pharmaceutical-like regulation have grown louder from consumer advocacy groups and medical professionals. They argue for mandatory pre-market approval and robust evidence for health claims. Nonetheless, regulatory bodies like the FDA and FTC face a complex balancing act. They must weigh these legitimate safety concerns against the risk of stifling industry innovation, increasing consumer costs, and limiting public access to popular and generally safe wellness products. The central challenge, therefore, lies in crafting a regulatory model that protects consumers from harm without extinguishing the innovation and accessibility that define the category [49].

In order to summarize the regulatory requirements, Nutraceuticals are mainly regulated as foods or dietary supplements rather than as drugs, lacking requirements for mandatory clinical trials and rigorous efficacy data. This regulatory framework prioritizes consumer safety and honest labelling over demonstration of therapeutic benefit, which fundamentally separates nutraceuticals from the pharmaceutical sector in most countries.

The absence of mandatory clinical trials for nutraceuticals creates significant safety concerns that directly impact consumer health. Unlike pharmaceuticals, which undergo extensive pre-market testing, nutraceuticals enter the market with minimal safety validation, leading to several critical safety issues.

Future Directions

The future of nutraceutical delivery is heading toward even smarter, more personalized systems:

- *Smart and Responsive Delivery:* Developing "intelligent" systems that release their payload only in response to specific triggers in the body, like a change in pH (e.g., in the intestine), the presence of certain enzymes, or redox potential [50].
- *3D Food Printing:* Using 3D printing technology to create personalized food products with precise, controlled doses of encapsulated nutraceuticals tailored to an individual's specific health needs [51].
- *Gut Microbiome Targeting:* Designing delivery systems that can selectively deliver prebiotics and probiotics to specific regions of the colon to positively influence the gut microbiome.
- *Novel Biomaterials:* Exploring new, sustainable, and edible materials like exosomes, starch-based nanoparticles, and protein-polysaccharide complexes for safer and more effective delivery [52].

CONCLUSION

The significant gap between the powerful therapeutic potential of nutraceuticals and their frustratingly low bioavailability in the human body has been a major roadblock. Advanced delivery systems, built on the principles of material science and pharmaceutical technology, are now providing the critical tools to overcome this barrier. By using lipid-based nanocarriers, polymeric nanoparticles, and sophisticated hybrid systems, we can effectively shield sensitive compounds, enhance their solubility, control their release, and guide them to their target.

This technological evolution is transforming nutraceuticals from poorly absorbed supplements into reliable, potent, and clinically relevant agents for preventive and therapeutic health. As we continue to innovate with smarter materials and more precise engineering, the future of nutrition is shifting toward personalized, effective, and evidence-based solutions, fully realizing the promise of "food as medicine."

REFERENCES

1. Grand View Research. Nutraceuticals Market Size, Share and Trends Analysis Report. Market Analysis Report. 2024.
2. Kalra EK. Nutraceutical--definition and introduction. *AAPS PharmSci*. 2003;5(3):27–8.
3. Gupta RC, Lall R, Srivastava A, Sinha A. Nutraceuticals in chronic diseases: Mechanisms of action. *J Diet Suppl*. 2023;20(1):1–25.
4. McClements DJ, Xiao H. Designing food structure to control stability, digestion, release and absorption of lipophilic food components. *Food Biophys*. 2017;12(1):1–12.
5. Rein MJ, Renouf M, Cruz-Hernandez C, Actis-Goretta L, Thakkar SK, da Silva Pinto M. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. *Br J Clin Pharmacol*. 2013;75(3):588–602.
6. Augustin MA, Sanguansri L. Challenges and solutions to incorporation of nutraceuticals in foods. *Annu Rev Food Sci Technol*. 2015;6:463–77.
7. Fang Z, Bhandari B. Encapsulation of polyphenols--a review. *Trends Food Sci Technol*. 2010;21(10):510–23.
8. Dudeja P, Gupta RK, editors. Nutraceuticals and Health: Review of Human Evidence. Boca Raton: CRC Press; 2021.
9. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807–18.
10. Walle T. Bioavailability of resveratrol. *Ann N Y Acad Sci*. 2011;1215(1):9–15.
11. Ezhilarasi PN, Karthik P, Chhanwal N, Anandharamakrishnan C. Nanoencapsulation techniques for food bioactive components: a review. *Food Bioprocess Technol*. 2013;6(3):628–47.
12. Huang Q, Yu H, Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. *J Food Sci*. 2010;75(1):R50-7.
13. Das L, Bhaumik E, Raychaudhuri U, Chakraborty R. Role of nutraceuticals in human health. *J Food Sci Technol*. 2012;49(2):173–83.
14. Gupta RC, Srivastava A, Lall R. Nutraceuticals in the management of disease. In: Gupta RC, Srivastava A, Lall R, editors. Nutraceuticals in Veterinary Medicine. Cham: Springer; 2018. p. 1–13.
15. Santini A, Novellino E, Armini V, Ritieni A. Nutraceuticals: A paradigm of proactive medicine. *Eur J Pharm Sci*. 2013;48(2-3):1–3.
16. Dima C, Assadpour E, Dima S, Jafari SM. Bioavailability and bioaccessibility of food bioactive compounds; overview and assessment by in vitro methods. *Compr Rev Food Sci Food Saf*. 2020;19(6):2862–84.
17. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*. 1995;12(3):413–20.
18. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. *Nat Rev Drug Discov*. 2007;6(3):231–48.
19. Parada J, Aguilera JM. Food microstructure affects the bioavailability of several nutrients. *J Food Sci*. 2007;72(2):R21-32.
20. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. *Am J Clin Nutr*. 2004;79(5):727–47.
21. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. *Mol Nutr Food Res*. 2008;52 Suppl 1:S139-51.
22. Bishop KS. Artificial Intelligence in Personalized Nutrition. *Trends Food Sci Technol*. 2022;119:508–19.
23. Chen L, Park A. Advanced Delivery Systems for Nutraceuticals: Liposomal and Nanoparticle Approaches. *J Funct Foods*. 2021;87:104836.

24. Sharma M, Wasan A, Sarma DK. Postbiotics: The New Frontier in Microbiome Science. *Gut Microbes*. 2023;15(1):2188845.
25. Global Wellness Institute. The Future of Wellness: Precision Fermentation and Cellular Agriculture. GWI Report. 2023.
26. McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. *Soft Matter*. 2012;8(6):1719–29.
27. Sessa M, Balestrieri ML, Ferrari G, Servillo L, Castaldo D, D'Onofrio N, et al. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. *Food Chem*. 2014;147:42–50.
28. Taylor TM, Weiss J, Davidson PM, Bruce BD. Liposomal encapsulation of food ingredients. In: Lakkis JM, editor. Encapsulation and Controlled Release Technologies in Food Systems. Oxford: Blackwell Publishing; 2005. p. 113–33.
29. Marsanasco M, Piotrkowski B, Calabró V, del Valle Alonso S, Chiaramoni NS. Bioactive constituents in liposomes incorporated into orange juice as new functional food: thermal stability, rheological and organoleptic properties. *J Food Sci Technol*. 2016;53(6):2644–52.
30. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery--a review of the state of the art. *Eur J Pharm Biopharm*. 2000;50(1):161–77.
31. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. *Int J Pharm*. 2002;242(1-2):121–8.
32. Aditya NP, Macedo AS, Doktorovova S, Souto EB, Kim S, Chang PS, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: A comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). *LWT Food Sci Technol*. 2014;59(1):115–21.
33. Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. *Eur J Pharm Biopharm*. 2012;81(3):463–9.
34. Krasaekoopt W, Bhandari B, Deeth H. Evaluation of encapsulation techniques of probiotics for yoghurt. *Int Dairy J*. 2003;13(1):3–13.
35. Wang Y, Padua GW. Formation of zein microphases in ethanol-water. *Langmuir*. 2010;26(15):12897–901.
36. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. *J Control Release*. 2012;161(2):505–22.
37. Goyal A, Kumar S. Polymeric micelles as emerging carrier for drug delivery in nutraceuticals. *J Polym Compos*. 2021;9(2):45–58.
38. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. *Eur J Pharm Biopharm*. 2007;65(3):259–69.
39. Bombardelli E, Curri SB, Loggia DR, Del Negro P, Tubaro A. Complexes between phospholipids and vegetal derivatives of biological interest. *Fitoterapia*. 1989;60(Suppl 1):1–9.
40. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. *Altern Med Rev*. 2009;14(3):226–46.
41. Gómez-Mascaraque LG, López-Rubio A, Martinez-Abad A. Electrosprayed gelatin submicroparticles as edible carriers for the encapsulation of polyphenols of interest in functional foods. *Food Hydrocoll*. 2016;55:41–53.
42. Neo YP, Ray S, Jin J, Gizdavic-Nikolaidis M, Nieuwoudt MK, Liu D, et al. Encapsulation of food grade antioxidant in natural biopolymer by electrospinning technique: a physicochemical study based on zein--gallic acid system. *Food Chem*. 2013;136(2):1013–21.
43. Sloan AE. The top ten functional food trends. *Food Technol*. 2002;56(4):32–57.
44. Garti N, Yuli-Amar I. Micro-and nano-emulsions for delivery of functional food ingredients. In: Garti N, editor. Delivery and Controlled Release of Bioactives in Foods and Nutraceuticals. Cambridge: Woodhead Publishing; 2008. p. 149–83.
45. Ghasemi S, Jafari SM, Assadpour E, Khomeiri M. Nanoencapsulation of d-limonene within nanocarriers produced by pectin-whey protein complexes. *Food Hydrocoll*. 2018;77:152–62.
46. Katouzian I, Jafari SM. Nano-encapsulation as a promising approach for targeted delivery and controlled release of vitamins. *Trends Food Sci Technol*. 2016;53:34–48.

47. Patil H, Tiwari RV, Repka MA. Hot-melt extrusion: from theory to application in pharmaceutical formulation. *AAPS PharmSciTech*. 2016;17(1):20–42.
48. Jafari SM, McClements DJ. Nanotechnology approaches for increasing nutrient bioavailability. In: Henry J, editor. Advances in Food and Nutrition Research. Vol. 81. Cambridge: Academic Press; 2017. p. 1–30.
49. EFSA Scientific Committee. Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. *EFSA J*. 2011;9(5):2140.
50. Timilsena YP, Akanbi TO, Khalid N, Adhikari B, Barrow CJ. Complex coacervation: principles, mechanisms and applications in microencapsulation. *Int J Biol Macromol*. 2019;121:1276–86.
51. Godoi FC, Prakash S, Bhandari BR. 3d printing technologies applied for food design: Status and prospects. *J Food Eng*. 2016;179:44–54.
52. Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. *Pharm Res*. 2001;18(5):557–64.

